Predictive Biomarker Testing for Programmed Cell Death 1 Inhibition in Non-Small Cell Lung Cancer

被引：0
|
作者：
Sheffield, Brandon S. [1 ]
Geller, Georgia [2 ]
Pleasance, Erin [3 ]
Zachara-Szczakowski, Susanna [1 ]
Milne, Katy [4 ]
Kalloger, Steve E. [1 ]
Zhao, Eric [3 ]
Bidnur, Samir [5 ]
Jones, Martin [3 ]
Nelson, Brad H. [4 ]
Yip, Stephen [1 ]
Marra, Marco A. [3 ]
Laskin, Janessa [2 ]
Ho, Cheryl [2 ]
Ionescu, Diana [1 ]
机构：
[1] BC Canc Agcy, Pathol, Vancouver, BC, Canada
[2] BC Canc Agcy, Med Oncol, Vancouver, BC, Canada
[3] BC Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC, Canada
[4] BC Canc Agcy, Deeley Res Ctr, Vancouver, BC, Canada
[5] Univ British Columbia, Urol Sci, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
PD-L1; Immunotherapy; biomarker; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL13.05
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [1] Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice
    Mino-Kenudson, Mari
    CANCER CYTOPATHOLOGY, 2017, 125 (07) : 521 - 528
  • [2] Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Yu, Hui
    Brustugun, Odd Terje
    Ekman, Simon
    Botling, Johan
    La Fleur, Linnea
    Micke, Patrick
    Solberg, Steinar
    Berglund, Anders
    Rivard, Christopher
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2021, 22 (04) : E555 - E562
  • [3] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [4] Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
    Dong, Zhengwei
    Liu, Yiwei
    Jiang, Tao
    Hou, Likun
    Wu, Fengying
    Gao, Guanghui
    Li, Xuefei
    Zhao, Chao
    Wang, Yan
    Yang, Shuo
    Mao, Shiqi
    Liu, Qian
    Li, Yumei
    Xu, Chuan
    Wu, Chunyan
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    Hirsch, Fred R.
    JOURNAL OF CANCER, 2020, 11 (03): : 551 - 558
  • [5] Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
    Acheampong, Emmanuel
    Spencer, Isaac
    Lin, Weitao
    Ziman, Melanie
    Millward, Michael
    Gray, Elin
    CANCERS, 2019, 11 (07)
  • [6] Predictive biomarker testing rates in patients with metastatic non-small cell lung cancer in The Netherlands
    de Jager, V.
    Garcia, B. N. Cajiao
    Kuijpers, C. C.
    de Bock, G. H.
    Maas, W. J.
    Timens, W.
    van Kempen, L. C.
    van der Wekken, A. J.
    Schuuring, E.
    Willems, S. M.
    VIRCHOWS ARCHIV, 2024, 485 : S139 - S140
  • [7] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [8] Predictive biomarker analysis of non-small cell lung cancer patients
    Sakellariou, S.
    Karatrasoglou, E. A.
    Chatziandreou, I.
    Giannopoulou, I.
    Michelli, M.
    Zougros, A.
    Rouppou, E.
    Stamopoulos, K.
    Lazaris, A. C.
    Korkolopoulou, P.
    Saetta, A.
    VIRCHOWS ARCHIV, 2019, 475 : S105 - S105
  • [9] Non-Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment
    Aisner, Dara L.
    Riely, Gregory J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 610 - 613
  • [10] Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Gainor, Justin F.
    CANCER CYTOPATHOLOGY, 2017, 125 (08) : 591 - 593
12345